scholarly journals Use of Anti-VEGF Agents and Lasers in Behçet s Disease

2018 ◽  
pp. 376-379
Keyword(s):  
Macular Edema ◽  
Laser Treatment ◽  
Cystoid Macular Edema ◽  
Secondary Glaucoma ◽  
Secondary Cataract ◽  
Anti Vegf ◽  
Functional Benefit ◽  
Management Of Complications ◽  
Retinal Tears

Ocular form of Behçet s Disease may end up in several complications. Anti-vasculoendothelial (anti-VEGF) agents and/or laser treatment are used in the management of these complications. Intravitreal Anti-VEGF agents are employed in Behçet s Disease for the management of cystoid macular edema (CME) and neovascularization (NV). Bevacizumab is reported to be effective for CME in some studies, however, there are also articles reporting that it does not provide significant anatomic or functional benefit. In Behçet s Disease laser treatment is indispensable in the management of complications like secondary glaucoma, secondary cataract, retinal tears, and retinal NV.

scholarly journals Treatment of cystoid macular edema in a patient with primary open angle glaucoma and diabetic retinopathy by withdrawal of travoprost

2021 ◽  
Vol 7 (2) ◽  
pp. 180-183
Author(s):  
Shiv Sagar N ◽  
BN Kalpana ◽  
Shilpa YD
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Laser Treatment ◽  
Proliferative Diabetic Retinopathy ◽  
Cystoid Macular Edema ◽  
Open Angle Glaucoma ◽  
Eye Drops ◽  
Antiglaucoma Medication ◽  
Micropulse Laser

To study the association of cystoid macular edema (CME) and Travoprost eye drops in a patient with diabetic retinopathy (DR).The study was carried out on a 65yr old patient on a regular follow up from 2009-2018.A 65yr old patient of a DR of both eyes who had received 3 sittings of pan retinal photocoagulation (PRP) laser in both eyes and grid laser to his right eye. He was on regular follow up since 2009 with a stable proliferative diabetic retinopathy (PDR). Patient was also on topical antiglaucoma medication and had prophylactic YAG-PI done both eyes. He was on regular follow up since 2009 with a stable proliferative diabetic retinopathy (PDR). Right eye showed macular edema (ME) in 2014 and underwent OCT and FFA. Patient refused for intravitreal injection and preferred laser treatment, so patient underwent micropulse laser treatment in 2014. His edema persisted even after micropulse treatment. His systemic control was good and patient continued to use Travoprost eye drops. So in 2017 suspected CME secondary to topical prostaglandin (PG) analogue as he had strict glycemic control and was no fluctuation in ME. Hence topical PG analogue was withdrawn and stopped. On subsequent follow up after 2 months CME had completely disappeared and the foveal contour returned to normal on OCT. LE was status quo. Patient was followed up for more than 1 year and continuously followed up, 15 days back in June 2018 had no evidence of CME and vision was 6/9 in both eyes.: Differentiation of DME and CME secondary to PG analogue should be made at the earliest.

Subthreshold micropulse yellow laser for the management of refractory cystoid macular edema consequent to complicated cataract surgery

2020 ◽  
pp. 112067212092800
Author(s):  
Tommaso Verdina ◽  
Cecilia Ferrari ◽  
Edoardo Valerio ◽  
Alberto Brombin ◽  
Andrea Lazzerini ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Cataract Surgery ◽  
Macular Edema ◽  
Laser Treatment ◽  
Cystoid Macular Edema ◽  
Foveal Thickness ◽  
Corrected Visual Acuity ◽  
Complicated Cataract ◽  
Yellow Laser ◽  
Best Corrected Visual Acuity

Purpose: To report the safety and efficacy of subthreshold micropulse yellow laser of 577 nm for a complex case of refractory pseudophakic cystoid macular edema. Methods: A retrospective chart review of an interventional case report of three subthreshold micropulse yellow laser interventions for refractory pseudophakic cystoid macular edema. Patient: A 77-year-old healthy female underwent pseudoexfoliative cataract surgery complicated by posterior capsule rupture and sulcus intraocular lens implantation. After 3 months, she required a scleral fixation of the same lens, due to a lack of capsular support and decentration of the intraocular lens. One month later, she experienced a severe pseudophakic cystoid macular edema (foveal thickness of 399 µm and best-corrected visual acuity of 20/80 Snellen). The condition was refractory to conventional treatments prior to subthreshold micropulse yellow laser interventions, including non-steroidal anti-inflammatory eye drops, topical steroids, oral indomethacin and three sub-Tenon’s triamcinolone injections, attempted over a 14-month period. Results: Subthreshold micropulse yellow laser treatment was performed and immediate resolution was achieved and maintained for 2 months. Two cases of edema relapse were observed at 3 months from initial laser treatment and again at 4 months from the second laser treatment. Final patient’s follow-up at 6 months from the third laser treatment evidenced the absence of edema, improved visual acuity (foveal thickness of 265 µm/best-corrected visual acuity of 20/30 Snellen) and the absence of complications. Conclusions: Subthreshold micropulse yellow laser seems to be a safe and effective treatment for short-term resolution of refractory pseudophakic cystoid macular edema after complicated cataract surgery and represents a useful alternative to expensive and invasive therapies. A trend towards a longer duration of edema resolution with every subthreshold micropulse yellow laser repetition was observed.

scholarly journals Cystoid Macular Edema after Extracapsular Cataract Extraction Performed by Residents

2020 ◽  
Vol 36 (3) ◽  
Author(s):  
Adnan Alam ◽  
Mohammad Idris ◽  
Hassan Yaqoob ◽  
Eemaz Nathaniel ◽  
Syed Ittrat Hussain ◽  
...  
Keyword(s):  
Macular Edema ◽  
Cystoid Macular Edema ◽  
Intravitreal Bevacizumab ◽  
Cataract Extraction ◽  
Hypertensive Retinopathy ◽  
Extracapsular Cataract Extraction ◽  
Retinal Degenerations ◽  
Intravitreal Bevacizumab Injection ◽  
Anti Vegf ◽  
Central Subfield Thickness

Purpose: To determine the frequency and outcome of management of cystoid macular edema after extracapsular cataract extraction performed by residents.Study Design: Interventional case series.Place and Duration of Study: Lady Reading Hospital, MTI, Peshawar from Oct 2018 to Oct 2019.Material and Methods: Total 400 patients with mature cataract were included in our study. Patients having preexistingdisease such as uveitis, hypertensive retinopathy, diabetic retinopathy and retinal degenerations wereexcluded. All surgeries were performed by 4th year residents under supervision. Complicated cases before orduring surgery were excluded from the study. Cystoid macular edema cases were classified as follows; acuteoccurring within three months of cataract extraction and with duration fewer than 6 months, chronic persistingmore than 6 months. Patients were either managed conservatively or with anti-VEGF. All cases were followed for3 months or longer until resolution of cystoid macular edema.Results: Twenty patients developed cystoid macular edema out of which 16 patients (80%) improved withconservative treatment and 4 patients (20%) developed resistant cystoid macular edema. All four patients weregiven intravitreal bevacizumab injection monthly for three months. Our findings showed that best corrected visualacuity (BCVA) before injection ranged from 6/60 to 6/24. After three injections BCVA improved between 6/18 to6/6. Pre injection central subfield thickness (CSFT) was between 611 to 480 micron which improved to 272 -260micron after injections.Conclusion: Cystoid macular edema responds well to conservative treatment but resistant cases need repeatedinj of anti VEGF.

scholarly journals Dramatic Resolution of Recalcitrant Cystoid Macular Edema after Concurrent Intravitreal Injection of Bevacizumab and Triamcinolone

2020 ◽  
Keyword(s):  
Macular Edema ◽  
Triamcinolone Acetonide ◽  
Cystoid Macular Edema ◽  
Vision Loss ◽  
Intravitreal Bevacizumab ◽  
Visual Outcome ◽  
Intravitreal Triamcinolone ◽  
Concurrent Treatment ◽  
Intravitreal Triamcinolone Acetonide ◽  
Anti Vegf

Background: Cystoid macular edema (CME), a common complication of branch retinal vein occlusion (BRVO), is associated with a significant vision loss. Anti-vascular endothelial growth factor (anti-VEGF) therapy is the gold standard of treatment, while grid macular photocoagulation has also been used as an adjuvant in patients with CME secondary to BRVO. More recent efforts were successful by the use of intravitreal triamcinolone acetonide. We proposed a concurrent use of intravitreal triamcinolone acetonide and intravitreal bevacizumab in the treatment of CME secondary to BRVO. Case presentation: We described an 82-year-old female with a BRVO in the right eye who developed associated CME. Repeated injections of intravitreal bevacizumab and modified grid macular laser treatment were ineffective. A concurrent treatment with intravitreal bevacizumab and triamcinolone acetonide resulted in complete and dramatic resolution of CME with a favorable visual outcome. Optical Coherence Tomography (OCT) demonstrated a significant decrease in central subfield thickness (CST) from 764μm to 253μm, without any post-procedure complications or recurrence of macular edema with complete recovery of visual acuity at 6-month follow-up. Conclusion: Early concurrent treatment with intravitreal anti-VEGF therapy (e.g. intravitreal bevacizumab) and intravitreal triamcinolone acetonide is likely to be more effective than intravitreal anti-VEGF agents alone or grid macular photocoagulation in the management of CME associated with BRVO.

scholarly journals Dramatic Resolution of Recalcitrant Cystoid Macular Edema after Concurrent Intravitreal Injection of Bevacizumab and Triamcinolone

2020 ◽  
Vol 9 (3) ◽  
pp. 159-163
Author(s):  
Kakarla V. Chalam ◽  
Suzie Gasparian ◽  
Moises Enghelberg
Keyword(s):  
Macular Edema ◽  
Triamcinolone Acetonide ◽  
Cystoid Macular Edema ◽  
Vision Loss ◽  
Intravitreal Bevacizumab ◽  
Visual Outcome ◽  
Intravitreal Triamcinolone ◽  
Concurrent Treatment ◽  
Intravitreal Triamcinolone Acetonide ◽  
Anti Vegf

Background: Cystoid macular edema (CME), a common complication of branch retinal vein occlusion (BRVO), is associated with a significant vision loss. Anti-vascular endothelial growth factor (anti-VEGF) therapy is the gold standard of treatment, while grid macular photocoagulation has also been used as an adjuvant in patients with CME secondary to BRVO. More recent efforts were successful by the use of intravitreal triamcinolone acetonide. We proposed a concurrent use of intravitreal triamcinolone acetonide and intravitreal bevacizumab in the treatment of CME secondary to BRVO. Case presentation: We described an 82-year-old female with a BRVO in the right eye who developed associated CME. Repeated injections of intravitreal bevacizumab and modified grid macular laser treatment were ineffective. A concurrent treatment with intravitreal bevacizumab and triamcinolone acetonide resulted in complete and dramatic resolution of CME with a favorable visual outcome. Optical Coherence Tomography (OCT) demonstrated a significant decrease in central subfield thickness (CST) from 764μm to 253μm, without any post-procedure complications or recurrence of macular edema with complete recovery of visual acuity at 6-month follow-up. Conclusion: Early concurrent treatment with intravitreal anti-VEGF therapy (e.g. intravitreal bevacizumab) and intravitreal triamcinolone acetonide is likely to be more effective than intravitreal anti-VEGF agents alone or grid macular photocoagulation in the management of CME associated with BRVO.

scholarly journals Emerging Therapies for the Treatment of Central Retinal Vein Occlusion and Macular Edema

2019 ◽  
pp. 54-57
Keyword(s):  
Macular Edema ◽  
Laser Treatment ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Current Treatment ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Emerging Therapies ◽  
New Applications ◽  
Central Retinal Vein

Many agents are used in the current treatment of central retinal vein occlusion and its complications. These treatments include anti-VEGF agents and steroids. Laser treatment is still up to date. In addition, many treatments are being developed outside the routine are being studied. In this review, treatments and new applications other than anti-VEGF, steroids, and laser used in the treatment of central retinal vein occlusion and macular edema will be reviewed.

Sign in / Sign up

Export Citation Format

Share Document